Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cidara Therapeutics, Inc. - Common Stock (NQ:CDTX)

218.41 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cidara Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Why Cidara Therapeutics Was Such a Healthy Stock Today ↗
The company could have quite a winner on its hands with its most advanced pipeline drug. 
Via The Motley Fool
Lithium Americas, Alibaba, uniQure, IREN, Cidara: Stocks Making The Biggest Moves Today ↗
Via Stocktwits
News headline image
Why Cidara Therapeutics, Already Up 173% This Year, Just Hit A Five-Year High ↗
The company is accelerating plans to run Phase 3 testing of its non-vaccine flu prevention drug by six months. 
Via Investor's Business Daily
Topics Intellectual Property
News headline image
Cidara (CDTX) Q2 Cash Surges 163% ↗
Via The Motley Fool
News headline image
Earnings Scheduled For August 7, 2025 ↗
 
Via Benzinga
News headline image
Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains ↗
With major rallies and analyst backing, Nektar, Cidara, and GeneDx are drawing interest; will these biopharma firms maintain their growth trajectories? 
Via MarketBeat
News headline image
Earnings Scheduled For May 8, 2025 ↗
 
Via Benzinga
News headline image
FedEx Issues Soft Guidance, Joins Torrid Holdings, Allot And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why BlackBerry Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Applied Materials To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
Cidara Therapeutics Stock Jumps After-Hours As Strong Flu Trial Data Outweighs $250M Share Offering ↗
The offering is being led by J.P. Morgan, Morgan Stanley, Guggenheim Securities, and Cantor. 
Via Stocktwits
News headline image
What's going on in today's session ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
Cidara Therapeutics’ Market Cap Doubles After Investigational Drug Shows Positive Results In Preventing Influenza In Mid-stage Trial ↗
Single doses of 450mg, 300mg, and 150mg of CD388 conferred 76%, 61%, and 58% protection, respectively, from symptomatic influenza over 24 weeks compared to placebo, the company said. 
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Crude Oil Falls 1%; US Services PMI Declines In June ↗
 
Via Benzinga
News headline image
Which stocks are experiencing notable movement on Monday? ↗
Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
News headline image
Cidara Launches 93% As A Universal Flu Shot Becomes A Closer Reality ↗
The midstage study hit all its goals, representing a "best case" scenario, according to one analyst. 
Via Investor's Business Daily
News headline image
Why Is Cidara Therapeutics Stock Trading Higher On Monday? ↗
Cidara's CD388 met key goals in a Phase 2b flu trial, showing strong efficacy and safety data, with FDA talks planned for advancing to Phase 3. 
Via Benzinga
News headline image
Dow Jumps Over 200 Points; FactSet Research Shares Gain After Q3 Results ↗
 
Via Benzinga
Topics Stocks
News headline image
These stocks are gapping in today's session ↗
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday. 
Via Chartmill
News headline image
These stocks are moving in today's pre-market session ↗
Discover the top movers in Monday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Cidara Therapeutics' Unique Cloudbreak Platform And Its Promise In Influenza And Oncology ↗
CDTX sold its Rezayo business to concentrate on its MDC-producing Cloudbreak platform which has already produced several promising drug candidates, like CD388, a very promising clinical-stage... 
Via Talk Markets
News headline image
This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗
 
Via Benzinga
News headline image
CDTX Stock Earnings: Cidara Therapeutics Beats EPS, Misses Revenue for Q2 2024 ↗
CDTX stock results show that Cidara Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
CDTX INVESTOR NOTICE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Regulatory Compliance
CDTX INVESTOR NOTICE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX
WHY: NEW YORK, NY - (NewMediaWire) - May 16, 2024 - Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Cidara... 
Via TheNewswire.com
Topics Regulatory Compliance
News headline image
CDTX Stock Earnings: Cidara Therapeutics Misses EPS, Misses Revenue for Q1 2024 ↗
CDTX stock results show that Cidara Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.